ASCO 2017: FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry

Chicago, IL ( Residual disease is a frequent finding after chemotherapy for metastatic testicular seminoma, seen in 55-80% of patients. Watchful waiting is recommended for residual lesions < 3 cm or lesions ≥3 cm with negative FDG-PET scan. In seminoma postchemotherapy residual masses of up to 3 cm represent necrosis in 97-100% and FDG-PET is not recommended. FDG-PET has a high negative predictive value to discriminate viable tumor from necrosis. Positive predictive value for FDG-PET has been shown to be low: 25% if performed before 6 weeks after the end of chemotherapy and 69% after this cut off. There is lack of data regarding the optimal management strategy for FDG-PET positive residual lesions.

Dr. Cathomas presented a retrospective study within the G3 Group identifying 90 patients from 18 centers in 9 countries with metastatic seminoma and residual PET positive lesions after chemotherapy. Patients with non-seminomatous components at diagnosis were excluded. The authors analyzed the post PET management chosen and its impact on relapse and survival.

Overall the median follow-up was 28.1 (IQR 9.6-62) months. Median age at diagnosis was 41 (range 19 – 69) years. The primary tumor was gonadal in 67 pts (75%), retroperitoneal in 10 pts (11%) and mediastinal in 12 pts (13%). 64 patients (71%) had elevated LDH and 54 patients (60%) had elevated HCG. The median diameter of the largest residual mass was 4.9 (range 1.1 – 14) cm mainly located in the retroperitoneum (77%), pelvis (16%), mediastinum (17%) or lung (3%). Median time from last day of chemotherapy to PET scan was 6.9 (IQR 4.4 – 9.9) weeks.

Post PET management was repeated imaging in 51 pts, resection in 26 pts, biopsy in 9 pts, and radiotherapy in 4 pts. The histology of the resected specimen was necrosis only in 25 patients (78%) and vital seminoma in 7 cases (22%). No biopsy revealed vital seminoma. Relapses occurred after a median of 3.7 (IQR 1.7 – 9.3) months in 15 pts. Site of relapse was the area of residual disease in 14 pts (93%) and additional distant relapse in 3 patients (20%). All relapsed pts received successful salvage chemotherapy apart from one who died from treatment.

In summary, 17% of seminoma patients with a positive post chemotherapy FDG-PET relapsed and only 7/32 of the resected specimens (22%) seminoma was found. Relapses occur rapidly and can be successfully salvaged. Biopsies were not diagnostic in any of the reported cases. FDG-PET has a very low positive predictive value even if performed 6 weeks after the end of chemotherapy (19%). The authors recommend repeating an FDG-PET scan 8-12 weeks after a positive first FDG-PET scan. Resections of PET positive residuals may be performed after a 2nd positive scan, but represent an overtreatment for 70-80% of patients.

Presented By: Richard Cathomas, SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre
Twitter: @GoldbergHanan

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 – Chicago, Illinois, USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.